Insurance Coverage Information

PAH Pathways Interactive Resource Locator

PAH Pathways offers a wealth of resources including one-on-one support from PAH Pathways counselors in your area.
Learn more »

PAH Pathways^® counselors understand your patients' concerns when it comes to paying for their therapy. That's why they offer comprehensive and practical information to take some of the hassle out of dealing with reimbursement issues.

PAH Pathways counselors work with your specialty pharmacy to:

Verifying insurance
Assisting with claims appeals
Clarifying patients' co-payment amount before their prescription is filled
Offering information about financial assistance for eligible patients who are uninsured or who need help paying for their medication

Financial Assistance Programs

When your patients need help paying for Ventavis

There are a number of financial assistance programs—sponsored both by PAH Pathways and other sources—that may help eligible Ventavis patients pay for their therapy:

Ventavis Patient Assistance Program (VPAP) may provide Ventavis at no cost to eligible patients
Caring Voice Coalition (CVC)^† offers a PAH* co-pay assistance program for eligible patients^‡
- CVC may also provide assistance with insurance policy premiums, emergency financial needs, and peer support groups
- Contact CVC at 1-888-267-1440 or visit www.caringvoice.org

^† Caring Voice Coalition is a nonprofit, third-party organization.
^‡ Ineligible patients: Any patients whose prescriptions are paid for by the government, Medicare, Medicaid, VA/DOD (Tricare), or Indian Health Service, patients in Massachusetts and Puerto Rico, or where prohibited by law.

*Ventavis Indication:

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

Ventavis Important Safety Information:

Hypotension leading to syncope has been observed; Ventavis should therefore not be initiated in patients with systolic blood pressure less than 85 mmHg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension. Ventavis inhalation may cause bronchospasm and patients with a history of hyperreactive airway disease may be more sensitive. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Ventavis has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants.

Please see full Prescribing Information for Ventavis.

*Tracleer Indication:

Tracleer is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital systemic-to-pulmonary shunts (18%).

Considerations for use
Patients with WHO class II symptoms showed reduction in the rate of clinical deterioration and a trend for improvement in walk distance. Physicians should consider whether these benefits are sufficient to offset the risk of liver injury in WHO class II patients, which may preclude future use as their disease progresses.

Please see full Prescribing Information, including BOXED WARNING about liver injury and pregnancy.